Growth hormone secretagogues
Sermorelin
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending.
Also known as GHRH (1-29)
A growth-hormone-releasing hormone analog that prompts your own pituitary output rather than replacing it.
What it is
Sermorelin is the first 29 amino acids of natural GHRH — the active portion. It signals the pituitary to release growth hormone in the body's own pulsatile pattern, which preserves feedback control rather than overriding it the way exogenous HGH does.
What it's studied for
- Growth-hormone and IGF-1 response in adults
- Sleep quality and slow-wave sleep architecture
- Body composition and recovery in age-related GH decline
How it's used in practice
- Administered at night, when natural GH pulses are largest
- IGF-1 is the practical marker used to assess response
- Availability and formulation vary by pharmacy and change over time
What you should know before asking about it
- Prescribed only after evaluation and appropriate labs; not for everyone
- Contraindicated with active malignancy
- Common effects include injection-site reaction, flushing and water retention
- Prohibited in competitive sport
Frequently asked questions.
- What is Sermorelin?
- Sermorelin is the first 29 amino acids of natural GHRH — the active portion. It signals the pituitary to release growth hormone in the body's own pulsatile pattern, which preserves feedback control rather than overriding it the way exogenous HGH does.
- What is Sermorelin studied for?
- Published and ongoing research looks at growth-hormone and IGF-1 response in adults; sleep quality and slow-wave sleep architecture; body composition and recovery in age-related GH decline. These are areas of study, not promised outcomes.
- Is Sermorelin FDA-approved?
- Sermorelin is not FDA-approved as a finished product. It is prepared by licensed, FDA-registered compounding pharmacies and can be dispensed only on a prescription written after a physician evaluation.
- How is Sermorelin typically used?
- Administered at night, when natural GH pulses are largest IGF-1 is the practical marker used to assess response Availability and formulation vary by pharmacy and change over time Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
- What are the risks and unknowns with Sermorelin?
- Prescribed only after evaluation and appropriate labs; not for everyone Contraindicated with active malignancy Common effects include injection-site reaction, flushing and water retention Prohibited in competitive sport
Sources
- 1.Published literature on Sermorelin GHRH (1-29)— PubMed, U.S. National Library of Medicine
- 2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
- 3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
- 4.Test directory and patient service center locator— Quest Diagnostics
About this page
Written by the Elevate Clinical Team
Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on . Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.
This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.
More in Growth hormone secretagogues
Ipamorelin
A selective growth-hormone secretagogue studied for GH release without meaningful cortisol or prolactin rise.
CJC-1295
A GHRH analog with extended half-life, studied to raise baseline growth-hormone and IGF-1 signaling.
Tesamorelin
An FDA-approved GHRH analog with the strongest clinical evidence of any peptide for reducing visceral adipose tissue.